Germany's pharmaceutical industry faces potential decline due to new savings package

Germany's pharmaceutical sector is raising concerns over a new savings package for the statutory health insurance (GKV) system, arguing it could lead to substantial reductions in investment and innovation within the country. Industry players warn that a potential exit from the German market is a real threat if the government's planned interventions in drug price regulation proceed.

The industry already contributes significantly to stabilizing the GKV system, with an estimated 29 billion euros in 2025. Germany currently employs over 30 different instruments for regulating drug prices. Despite this, pharmaceutical companies have shouldered a disproportionate burden of previous cost-saving measures. For instance, in the 2022 GKV Financial Stabilization Act, the pharmaceutical industry was responsible for nearly 80 percent of all savings generated by providers.

The new GKV Contribution Stabilization Act, aimed at moderating healthcare costs, includes provisions that could disproportionately affect the industry. While the Federal Ministry of Health (BMG) acknowledges that some previous regulations have proven "inflexible and potentially innovation-hampering," the proposed new measures, such as a dynamized manufacturer rebate and proposals for volume-based pricing, are projected to result in a net burden of 5.75 billion euros for the industry by 2030. This represents nearly 19 percent of the total planned savings across all providers, despite the pharmaceutical manufacturers accounting for only about 12 percent of the GKV's overall expenditures.

For the market of innovative, patented drugs – the primary target of these new measures – the equivalent contribution to overall spending is around seven percent. The industry contests claims that it is being largely spared from the savings. It highlights that already, one out of every three new drugs approved in the U.S. does not reach patients in Germany. The industry fears that this innovation gap will widen, reducing access to new therapies for German patients.

Representatives from the pharmaceutical sector are urging the government to reconsider its plans. They argue for a more balanced approach that acknowledges the industry's vital role in both the economy and patient care, crucial for maintaining Germany's position as a leader in health and medical innovation in Europe.